What is liver fibrosis, including its causes, diagnosis, and management?

Liver Fibrosis: Definition, Causes, Diagnosis, and Management

Liver fibrosis is the excessive accumulation of extracellular matrix proteins (particularly collagen) that occurs as a wound-healing response to chronic liver injury, representing a critical pathological process that can progress to cirrhosis, liver failure, and hepatocellular carcinoma if left untreated. 1

What Is Liver Fibrosis?

Liver fibrosis develops when chronic inflammation persists in the liver, triggering scar-like changes through abnormal deposition of collagen and other matrix proteins. This process is characterized by activation of hepatic stellate cells, which transform into myofibroblasts and become the primary producers of fibrotic tissue. 2, 3 Importantly, early-stage fibrosis is potentially reversible if the underlying cause is eliminated, though advanced fibrosis and cirrhosis are often irreversible. 4, 1

The progression follows a predictable pathway: chronic injury → inflammation → hepatic stellate cell activation → extracellular matrix deposition → architectural distortion → cirrhosis → decompensation and complications. 5

Major Causes

The etiologies of liver fibrosis are diverse but share common pathogenic mechanisms:

Viral hepatitis (hepatitis B and C) remains a leading cause globally, though hepatitis C incidence is declining with effective antiviral therapies. 5

Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease are becoming the dominant drivers in developed countries. 5, 3, 6

Other important causes include:

• Autoimmune hepatitis
• Primary biliary cholangitis
• Primary sclerosing cholangitis
• Drug-induced liver injury
• Chronic cholestasis 5, 7

A critical pitfall: Alcohol metabolites (particularly acetaldehyde) directly activate hepatic stellate cells and generate oxidative stress, making alcohol cessation essential even in early disease. 2

Diagnosis and Staging

Liver Biopsy: The Historical Standard

Liver biopsy has traditionally been the reference standard for diagnosing and staging fibrosis, but it is invasive, costly, subject to sampling error, and poorly suited for longitudinal monitoring. 1, 5 The procedure requires adequate tissue—ideally 25mm length with a 16-gauge needle—to minimize sampling variability. 1

Common staging systems include:

• METAVIR score (F0-F4): Treatment typically recommended at F2 or higher
• Ishak score (0-6): Treatment typically recommended at stage 3 or higher 8

Non-Invasive Assessment: The Modern Approach

MR elastography is currently the most accurate imaging modality for diagnosing and staging hepatic fibrosis, outperforming ultrasound-based methods, particularly in patients with obesity. 5 This represents a paradigm shift from morphologic imaging (CT, MRI, ultrasound) which can only reliably detect advanced cirrhosis based on surface nodularity, caudate hypertrophy, and right lobe atrophy. 5

Blood-based biomarkers provide moderate diagnostic accuracy:

• FIB-4 index (age, AST, ALT, platelet count):

  • <1.45 effectively excludes advanced fibrosis

  • 3.25 suggests advanced fibrosis (F3-F4)

  • Superior to APRI for staging 9

• APRI (AST-to-platelet ratio index):

  • <0.5 excludes significant fibrosis

  • 1.5 suggests advanced fibrosis 9

Key limitation: These biomarkers show small-to-moderate changes in pretest probability and cannot reliably distinguish intermediate fibrosis stages. 9 They are most useful for ruling out advanced disease or identifying patients who need further evaluation.

Practical Diagnostic Algorithm

1. Initial assessment: Calculate FIB-4 and APRI in all patients with chronic liver disease
2. Low scores (FIB-4 <1.45): Advanced fibrosis unlikely; monitor clinically
3. High scores (FIB-4 >3.25): Advanced fibrosis likely; proceed to elastography or consider biopsy
4. Intermediate scores: Obtain MR elastography for definitive staging
5. Contraindications to elastography: Consider liver biopsy when results will influence treatment decisions 8, 5, 7

Management Strategies

Etiologic Treatment: The Foundation

Removing or suppressing the underlying cause of liver injury is the cornerstone of management and can lead to fibrosis regression in early disease. 4

• Viral hepatitis B: Antiviral therapy improves outcomes even in decompensated cirrhosis 4
• Hepatitis C: Direct-acting antivirals show beneficial effects on liver function and portal hypertension 4
• Alcohol-related disease: Complete abstinence is essential; some patients achieve "re-compensation" 4, 2
• MASLD: Sustained weight loss through lifestyle modification remains foundational 6

Critical caveat: Etiologic treatment is less effective in decompensated cirrhosis, and outcomes vary significantly between patients. 4

Emerging Pharmacologic Therapies

While no antifibrotic drugs are FDA-approved, several agents show promise in clinical trials for MASLD/MASH with moderate-to-advanced fibrosis (F2-F3):

• GLP-1 receptor agonists and dual/triple incretin agonists
• Thyroid hormone receptor-β agonists (resmetirom)
• FXR agonists (bile acid pathway modulators)
• PPAR agonists and FGF21 analogues 6

These therapies target metabolic stress, inflammation, and fibrogenesis, representing a shift toward mechanism-based treatment rather than solely addressing complications. 4, 6

Surveillance and Monitoring

Patients with cirrhosis require HCC surveillance every 6 months using ultrasound; in patients with poor ultrasound visualization (obesity, severe steatosis), multiphase CT or MRI may be appropriate. 5

For monitoring fibrosis progression in patients not on treatment, repeat assessment at 4-5 year intervals is reasonable. 8

Key Clinical Pitfalls

1. Don't rely on aminotransferase levels alone: 14-24% of patients with persistently normal ALT have significant fibrosis on biopsy 8

2. Recognize that fibrosis staging directly impacts prognosis: The amount of fibrosis correlates with risk of cirrhosis, decompensation, and hepatocellular carcinoma 1

3. Understand that cirrhosis complications drive mortality: Portal hypertension, variceal hemorrhage, ascites, hepatic encephalopathy, and HCC account for approximately 2 million deaths annually worldwide 5

4. Early intervention matters: Advanced fibrosis and cirrhosis are often irreversible, making early detection and treatment critical 4, 1

5. Combination approaches may be necessary: Single-agent therapy often proves insufficient in advanced disease; future strategies will likely involve stage-specific, mechanism-informed combinations 6